Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048659 · ClinicalTrials.gov registry record · Phase 2
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00048659 is a Phase 2 study that was terminated before completion, run by Astellas Pharma.
The verdict
NCT00048659, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
Interventions
- DRUG YM598
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2004-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048659
The ClinicalTrials.gov registry entry for NCT00048659 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which YM598 is the first listed.
NCT00048659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048659 about?
NCT00048659 is a clinical study titled "YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy". The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
What is the current status of trial NCT00048659?
This trial is currently terminated. It is a Phase 2 study. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00048659?
The interventions under investigation include: YM598 (DRUG).
Who is sponsoring clinical trial NCT00048659?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.